DP
PRQR icon

Diadema Partners’s ProQR Therapeutics PRQR Stock Holding History

Diadema Partners’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Buy
926,016
+745,933
+414% +$1.23M 0.22% 84
2026
Q1 		$292K Buy
180,083
+12,551
+7% +$20.6K 0.05% 120
2025
Q4 		$338K Buy
167,532
+9,838
+6% +$23K 0.06% 123
2025
Q3 		$336K Hold
157,694
– – 0.09% 105
2025
Q2 		$322K Sell
157,694
-50,000
-24% -$81.3K 0.1% 84
2025
Q1 		$276K Buy
207,694
+49,671
+31% +$106K 0.07% 90
2024
Q4 		$419K Buy
+158,023
New +$502K 0.18% 75

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Diadema Partners's PRQR Position: Q2 2026 in Review

Diadema Partners increased its ProQR Therapeutics (PRQR) stake by 414% in Q2 2026, buying an estimated $1.23M and bringing the position to 926,016 shares worth $1.72M. The position accounts for 0.22% of the portfolio, ranked #84.

Diadema Partners first reported a position in PRQR in Q4 2024 and has held it in 7 quarters since. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Diadema Partners held 926,016 shares of ProQR Therapeutics worth $1.72M as of Q2 2026.
  • Diadema Partners bought 745,933 ProQR Therapeutics shares in Q2 2026, an estimated $1.23M.
  • ProQR Therapeutics made up 0.22% of Diadema Partners's portfolio in Q2 2026, its #84 holding.
  • Diadema Partners first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.